Pfizer stops one of two Phase 3 trials for sickle cell drug, still plans to seek approval in 2026

Pfizer terminated one of two late-stage trials for a sickle cell treatment candidate from its $5.4 billion acquisition of Global Blood Therapeutics in 2022.

The pharma giant is still running a second Phase 3 for the drug, known as inclacumab, a spokesperson confirmed Tuesday to Endpoints News.

A Monday update to the federal clinical trials database shows that Pfizer ended a Phase 3 of inclacumab due to “poor accrual and associated [recruitment] challenges.” The study enrolled 72 people out of an originally planned 280, according to clinicaltrials.gov.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。